Prograf

Generic Name: Prograf

What is Prograf?

Avoid exposure to sunlight and UV light such as tanning machines. Grapefruit and grapefruit juice may interact with Prograf and lead to potentially dangerous effects. You and your doctor should decide if you will take Prograf or breastfeed. Take this medication exactly as prescribed by your doctor. Follow the directions on your prescription label carefully. The recommended initial dose of Prograf injection is 0. The recommended initial dose of Prograf capsules in children for preventing rejection of a liver transplant is 0.

Doses will then be adjusted based on assessment of organ rejection and how you are handling the medicine. If you take too much Prograf, call your doctor or go to the nearest hospital emergency room right away.

Ranolazine: Ranolazine is associated with dose- and plasma concentration-related increases in the QTc interval. The mean increase in QTc is about 6 milliseconds, measured at the tmax of the maximum dosage 1000 mg PO twice daily. Although there are no studies examining the effects of ranolazine in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation.

In addition, in vitro studies indicate that ranolazine and its metabolite are inhibitors of CYP3A isoenzymes. The impact of coadministering ranolazine with other CYP3A4 substrates has not been studied. Ranolazine may theoretically increase plasma concentrations of CYP3A4 substrates, potentially leading to adverse reactions, such as QT prolongation.

Drugs that are CYP3A4 substrates that also have a possible risk for QT prolongation and TdP that should be used cautiously with ranolazine include tacrolimus. Regadenoson: Regadenoson has been associated with QT prolongation. Drugs with a possible risk for QT prolongation and torsade de pointes that should be used cautiously with regadenoson include tacrolimus. Ribociclib: Avoid coadministration of ribociclib with tacrolimus due to an increased risk for QT prolongation and torsade de pointes TdP.

Concomitant use may increase the risk for QT prolongation. Ribociclib is also a moderate CYP3A4 inhibitor and tacrolimus is a sensitive CYP3A4 substrate with a narrow therapeutic window. Rifabutin: Coadministration with strong CYP3A4-inducers such as rifabutin is not recommended without adjustments in the dosing regimen of tacrolimus and subsequent close monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions.

How should I take Prograf?

Darunavir: Tacrolimus is a CYP3A4 substrate, and darunavir inhibits CYP3A4. Close monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions, and appropriate adjustments in the dosing regimen of tacrolimus are recommended. Extreme caution must be used when administering tacrolimus concomitantly with any anti-retroviral protease inhibitor.

Tacrolimus concentrations can be maintained with appropriate monitoring and dosage adjustment. Dasatinib: Due to a possible risk for QT prolongation and torsade de pointes TdPdasatinib and tacrolimus should be used together cautiously.

What should I avoid while taking Prograf?

Preventing the body rejecting a transplanted kidney, liver or heart Treating transplant rejection when other immunosuppressants have failed to control the rejection. Prograf capsules should be taken on an empty stomach, or at least one hour before or two to three hours after a meal.

This medicine may cause various side effects that could reduce your ability to drive or operate machinery safely. These effects may be enhanced by drinking alcohol. You should make sure you are aware of your reaction to this medicine before driving or operating machinary.

Prograf side effects

However, if concomitant therapy is necessary, close monitoring of tacrolimus blood concentrations and of the QT interval is warranted. Erythromycin administration is associated with QT prolongation and torsades de pointes TdP. Drugs with a possible risk for QT prolongation and TdP such as tacrolimus should be used cautiously with erythromycin. In addition, the concurrent administration of erythromycin and tacrolimus may result in elevated tacrolimus levels resulting in nephrotoxicity. Escitalopram: Escitalopram has been associated with QT prolongation.

Coadministration with other drugs that have a possible risk for QT prolongation and torsade de pointes TdPsuch as tacrolimus, should be done with caution and close monitoring. Eslicarbazepine: In vivo studies suggest eslicarbazepine is an inducer of CYP3A4. Eslicarbazepine may potentially accelerate the hepatic metabolism of tacrolimus.

Common Prograf ide effects may include:

  • According to the manufacturer of ferric citrate, clinicians should consider separating the timing of administration of ferric citrate and drugs where a reduction in the bioavailability of would have a clinically significant effect on its safety or efficacy.

  • Log in Find medicines with the same active ingredientsFind medicines from the same companyPrograf 0.

  • Nelfinavir: Nelfinavir is a potent inhibitor of CYP3A4 and is expected to inhibit the metabolism of tacrolimus, thus increasing whole blood concentrations of tacrolimus and leading to the potential for nephrotoxicity or other tacrolimus-related side effects.

  • Careful monitoring and possible dose adjustment of tacrolimus is recommended.

What should I avoid while taking ASTAGRAF XL. Live vaccines such as flu vaccine through your nose, measles, mumps, rubella, polio by mouth, TB vaccine, yellow fever, chicken pox or typhoid. You should not drink alcohol when taking ASTAGRAF XL.

ASTAGRAF XL may cause serious side effects, including: See "What is the most important information I should know about ASTAGRAF XL. People who take ASTAGRAF XL have sometimes been given the wrong medicine, because some medicines have the same ingredient tacrolimus as ASTAGRAF XL.

Where can I get more information?

  • Calcium Channel Blockers Verapamil, diltiazem, nifedipine, and nicardipine inhibit CYP3A metabolism of tacrolimus and may increase tacrolimus whole blood concentrations.

  • The manufacturer of tacrolimus states that coadministration with strong CYP3A4 inhibitors such as clarithromycin is not recommended without adjustments in the dosing regimen of tacrolimus and subsequent close monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions.